According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...
Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.
Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...
A new wave of immuno-therapies is reshaping the fight against cancer, turning the body’s own immune system into a powerful ...
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of ...
Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...
Theralase Technologies (TSXV:TLT) has shown in pre-clinical trials that its flagship Rutherrin, when activated by X-Ray, is ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
Baar, Switzerland Wednesday, March 4, 2026, 17:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results